written on 09.05.2014

U.K.'s NICE throws Astellas a bone on Xtandi–or does it?


First it was good news, then it was bad news, and now it's good news again for Astellas' prostate cancer treatment Xtandi (enzalutamide) and its recommendation from the U.K.'s National Institute for Health and Care Excellence. At least it appears that way.